I've been making some bad sell decisions Most likely because of the NFL Draft Blogging I am doing non stop./ Let me throw this out to you -- CARPENTER TECH-- I have a $4,000+ gain CRS./ HOLD? OR SELL AND BUY SOMETHING NEW?
ARE WE WATCHING ANYTHING-? WHO HAS A BUY IDEA? WHY IS IT ALWAYS ME? Viking Therapeutics, Inc. (VKTX)<-- I HATE THIS SYMBOL. 107 TIMES I'VE LOOKED IT UP AND NEVER ONCE GOT IT RIGHT... VIKE, VKNG, VBIO... NO! VKTX. NasdaqCM - NasdaqCM Real Time Price. 20.53+0.92 (+4.69%) As of 11:54AM EDT.
What is it to be an active trader? Well seeing a detergent plastic container and recycling it isn't enough. You want an entire factory and you want to change the world.... Thank You PureCycle holders.. children of the corn. PureCycle Technologies, Inc. (PCT) NasdaqCM - NasdaqCM Real Time Price. 6.52+0.44(+7.24%)<------------------ As of 11:56AM EDT.
Alright this is pathetic I am lookimg for any type pf watch list here and I find nada! what the hell>>> ARCO This is the only name I have on watch along with CCCS & Viking. Arcos Dorados Holdings Inc. (ARCO) NYSE - Nasdaq Real Time Price. 7.92+0.01(+0.13%) As of 12:04PM EDT. Market open.
What appened Shares of the clinical-stage biotechViking Therapeutics(VKTX4.21%)jumped by 7% almost right out of the gate Thursday morning. Thebiotech's shares, however, have cooled off as today's session has progressed. As of 2:19 p.m. ET Thursday afternoon, Viking's stock was only up by 0.72%. The biotech's shares briefly popped this morning in response to investing firm H.C. Wainwright raising its 12-month price target on the stock from $21 to $33 per share. This revised price target implies a 68% upside potential from current levels. So what Viking's shares have been racing higher over the past 12 months. In fact, the biotech's shares have climbed by an astounding 759% over this period. Viking's stock caught fire in response torenewed interestin its midstage nonalcoholic steatohepatitis (NASH) candidate VK2809, as well as strong early-stage results for its weight loss candidate VK2735. NASDAQ: VKTX Viking Therapeutics Today's Change (4.21%) $0.82 Current Price $20.43 VKTX KEY DATA POINTS Market Cap Day's Range $19.51 - $20.44 52wk Range $2.02 - $22.04 Volume 1,123,773 Avg Vol H.C. Wainwright's revised price target appears to reflect the growing optimism surrounding Viking's two most important value drivers. Fortunately, this optimism does have a basis in reality. The global NASH market may eventually generate over $30 billion a year in annual sales, whereas anti-obesity treatments are believed to be on track to rake in over $50 billion a year by the middle of the next decade. Now what Is Viking stock still a strong buy? It depends on your tolerance for risk. On the plus side, Viking is markedly undervalued relative to other top-tier metabolic disease specialists. So there is a chance that a massive valuation gap still exists with this red-hot equity. On the negative side, Viking is well behind the leaders in both NASH and obesity from a development standpoint. As such, the company will probably have to report stellar clinical trial data in these high-value settings in order to have a realistic shot at wrestling market share away from drugs already on the market.
Up $14 take profits & Revisit next week>>>>>>>> How much you loving stoney? SiteOne Landscape Supply, Inc. (SITE)- NYSE - Nasdaq Real Time Price. 147.56+4.07(+2.84%)<----------------
STONEY!!!! WILL IT HAPPEN LIKE I PREDICTED ---> 4200 ON 4/28 ???!!!! 35 POINTS TO GO YOU'RE WELCOME>>>> IN ADVANCE **** The emails are rolling in Stoney. They want you to call our next thread: "GBA Presents: The Daily Hot Sheet"